Neurol. pro Praxi, 2006; 6: 330-332

Sledování dlouhodobé účinnosti a snášenlivosti eletriptanu v akutní léčbě migrény

MUDr. Jiří Mastík1, MUDr. Jolana Marková2,3, MUDr. David Doležil Ph.D4, MUDr. Petr Dočekal5
1 Neurologická klinika LF MU a FN u sv. Anny, Brno
2 Neurologické oddělení Nemocnice Kladno, Regionální poradna pro diagnostiku a léčbu bolesti
3 Neurologická klinika, Fakultní Thomayerova nemocnice, Praha
4 Neurologická klinika FNsP Ostrava-Poruba
5 Neurologická klinika 1. LF UK a VFN, Praha

Autoři chtěli ve své práci ověřit dlouhodobou účinnost a snášenlivost eletriptanu v lokálních podmínkách. Eletriptan je selektivní agonista serotoninových receptorů (5-HT1B/1D), patřící do skupiny tzv. triptanů II. generace. Používá se k léčbě migrenózních záchvatů s aurou i bez aury, především střední a silné intenzity.

Keywords: migréna, akutní léčba, eletriptan, triptany

Published: February 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mastík J, Marková J, Doležil D, Dočekal P. Sledování dlouhodobé účinnosti a snášenlivosti eletriptanu v akutní léčbě migrény. Neurol. praxi. 2006;7(6):330-332.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brandes J, Sikes C, Hilliard B. Eletriptan in the early treatment of migraine: a prospective, double-blind, placebo-controlled trial. Eur J Neurol 2004; 11 (Suppl 2): 93. Go to original source...
    2. Caddy RK, Lipton RB, Hall C et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000; 40: 792-797. Go to original source... Go to PubMed...
    3. Diener HC, McHarg A. Pharmacology and efficacy of eletriptan for the treatment of migraine attacs. Int J Clin Pract 2000; 54: 670-674. Go to original source... Go to PubMed...
    4. Dočekal P. Zkušenosti s léčbou migrény eletriptanem. Bolest 2003; 6 (Suppl 2): 9.
    5. Färkkilä M. A dose finding study of eletriptan (20-80 mg) for the acute treatment of migraine. Cephalalgia 1996; 16: 368.
    6. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT 1B/1Dagonistys) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-1675. Go to original source... Go to PubMed...
    7. Géraud G, Kenwood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological and pharmacocinetic properties of triptans. Headache 2003; 43: 376-388. Go to original source... Go to PubMed...
    8. Goadsby PJ, Ferrari MD, Olesen J et al. Eletriptan in acute migraine: a double-blind, placebocontrolled comparison to sumatriptan. Neurology 2000; 54: 156-163. Go to original source... Go to PubMed...
    9. Chia YCh, Lim SH, Wang SJ et al. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs. Headache 2003; 43: 984-990. Go to original source... Go to PubMed...
    10. Jackson NC. A comparison of oral eletriptan (20-80 mg) and oral sumatriptan (100 mg) in the acute treatment of migraine. Cephalalgia 1996; 16: 368.
    11. Kathpal GS. Cluster headaches: pathogenesis, symptomatology and management. Cephalalgia 2000; 20: 327.
    12. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638-645. Go to original source... Go to PubMed...
    13. Mastík J, Slíva J. Eletriptan. Farmakoterapie 2005; 1: 257-262.
    14. Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003; 43: 962-974. Go to original source... Go to PubMed...
    15. Pascal J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002; 42: 28-31. Go to original source... Go to PubMed...
    16. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995; 35: 387-396. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.